And PCSK9 inhibitors are even the preferred lipid-lowering medications for high-risk patients with hemorrhagic stroke (including patients with a history of hemorrhagic stroke) (Sanz-Cuesta & Saver, 2021). This evidence concerns the gene PCSK9 and hemorrhagic stroke.